Pfizer Inc. (NYSE:PFE) Shares Sold by Cyrus J. Lawrence LLC

Cyrus J. Lawrence LLC trimmed its stake in Pfizer Inc. (NYSE:PFEFree Report) by 18.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,034 shares of the biopharmaceutical company’s stock after selling 667 shares during the period. Cyrus J. Lawrence LLC’s holdings in Pfizer were worth $100,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Valley Wealth Managers Inc. boosted its stake in Pfizer by 2.0% during the 3rd quarter. Valley Wealth Managers Inc. now owns 481,671 shares of the biopharmaceutical company’s stock worth $15,977,000 after purchasing an additional 9,479 shares during the period. One Capital Management LLC boosted its stake in Pfizer by 6.2% during the 3rd quarter. One Capital Management LLC now owns 190,244 shares of the biopharmaceutical company’s stock worth $6,310,000 after purchasing an additional 11,070 shares during the period. Alliance Wealth Advisors LLC UT boosted its stake in Pfizer by 18.3% during the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 17,611 shares of the biopharmaceutical company’s stock worth $584,000 after purchasing an additional 2,722 shares during the period. RS Crum Inc. acquired a new stake in Pfizer during the 3rd quarter worth $259,000. Finally, Rock Point Advisors LLC boosted its stake in Pfizer by 9.6% during the 3rd quarter. Rock Point Advisors LLC now owns 84,915 shares of the biopharmaceutical company’s stock worth $2,817,000 after purchasing an additional 7,447 shares during the period. 68.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were purchased at an average cost of $26.47 per share, with a total value of $79,410.00. Following the completion of the transaction, the director now directly owns 9,000 shares in the company, valued at approximately $238,230. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by insiders.

Pfizer Trading Up 0.9 %

Shares of NYSE PFE traded up $0.24 during midday trading on Monday, reaching $27.80. 5,807,815 shares of the stock were exchanged, compared to its average volume of 44,042,246. The company has a market capitalization of $156.97 billion, a P/E ratio of 76.56, a P/E/G ratio of 1.22 and a beta of 0.62. Pfizer Inc. has a 52-week low of $25.76 and a 52-week high of $44.20. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $28.19 and a 200-day moving average price of $31.36.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.61%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. Pfizer’s revenue was down 41.3% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.23 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, January 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. This is an increase from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 25th. Pfizer’s payout ratio is presently 466.67%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Morgan Stanley decreased their price target on shares of Pfizer from $39.00 to $37.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 1st. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, October 16th. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Truist Financial reduced their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Finally, Citigroup reduced their target price on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating for the company in a research note on Monday, October 16th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.93.

View Our Latest Research Report on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.